Home  »  Trendy Stocks   »  Autolus Therapeutics plc (AUTL) stock is soaring i...

Autolus Therapeutics plc (AUTL) stock is soaring in the premarket: Here’s Why

Shares of the Autolus Therapeutics plc (AUTL) stock soared in the premarket today on November 8, 2021. The stock became bullish after the announcement of a strategic collaboration and financing agreement with BlackStone Life Sciences. AUTL stock price saw a surge of 26.80% to reach $7.05 a share at the time of this writing. The stock was gloomy in the previous trade and went down by 1.59% at closing. Let’s discuss more this stock.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


Autolus Therapeutics plc is the biopharmaceutical stock that is focused to treat cancer diseases via the development of T cell therapies. The stock has a current market value of $405.43 million and 440,189 average trading volume.

BlackStone to invest in AUTL stock:

AUTL stock recently announced that it has signed a strategic collaboration and financing agreement with BlackStone Life sciences pursuant to which the latter will invest up to $250 million in the former. This funding will support the advanced development of CD19 CAR T cell investigational therapy product candidate of AUTL stock. The funding will also help Autolus stock in the next generation product therapies of obe-cel in B-cell malignancies.

According to the agreement, BlackStone will invest $150 million as product financing to support the development as well as commercialization of obe-cel development. $50 million will be payable upon the closing of the transaction and the rest of the amount will be payable based on certain developments and regulatory achievements. BlackStone will buy $100 million American Depository Shares of AUTL stock in a private placement subject to customary closing conditions. In connection with the agreement, BlackStone now has a right to nominate the board member of Autolus stock.

Financial View of AUTL stock:

According to third-quarter 2021 financial results, Autolus stock spent $40.4 million in operating expenses in the three months ended September 30, 2021. This compares to net operating expenses of $42.7 million in the same period of the previous year. Research and development expenses were $32.3 million and general and administrative expenses were $8.3 million in the third quarter of 2021. AUTL stock suffered a net loss of $34.0 million in the third quarter of 2021 as compared to $37.3 million for the same tenure of the previous year. By the end of the third quarter, AUTL stock had $173.1 million total in cash as compared to $216.4 million by the end of the second quarter of 2021.

Wrap Up:

AUTL stock has captivated the attention of investors after the announcement of its strategic collaboration and financing agreement with BlackStone. The financing from BlackStone is a good sign for AUTL stock in terms of its clinical developments.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam